- Show all
- Abigail Coursolle
- Brian Brooks
- Fabiola Carrión
- Amy Chen
- daryln
- Corey Davis
- Andrew DiAntonio
- Elizabeth Edwards
- Candace Gibson
- Sarah Grusin
- Héctor Hernández-Delgado
- Rachel Holtzman
- Priscilla Huang
- Alicia Kauk
- Jennifer Lav
- Leonardo Cuello
- Jeremy Leaming
- Kimberly Lewis
- lhigashi
- lmilani
- David Machledt
- Elizabeth McCaman
- Catherine McKee
- Joe McLean
- Michelle Lilienfeld
- National Health Law Program Team
- Hayley Penan
- Jane Perkins
- Alexis Robles
- Susan Berke Fogel
- Sarah Somers
- Elizabeth G. Taylor
- veng
- Wayne Turner
- Mara Youdelman
- Show all
- Alabama
- Alaska
- Arizona
- Arkansas
- California
- Colorado
- Connecticut
- District of Columbia
- Florida
- Georgia
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky
- Maine
- Maryland
- Massachusetts
- Michigan
- Mississippi
- Missouri
- Montana
- National
- New Hampshire
- New Mexico
- New York
- North Carolina
- Oklahoma
- Oregon
- Pennsylvania
- Tennessee
- Texas
- Utah
- Virginia
- Washington
- Show all
- Abortion
- Child and Adolescent Health
- CHIP
- Civil Procedure
- Civil Rights
- Cost-sharing
- Court Access
- Data Collection
- Defending Medicaid
- Demonstrations
- Disability Rights
- Dual Eligible Beneficiaries
- Eligibility and Enrollment
- EPSDT
- Exchanges/Marketplaces
- Family Planning
- HCBS/LTSS
- Health Care Reform
- Health Care Refusals
- Health Disparities
- Health Reform
- HIV/AIDS and Sexual Health
- Language Access
- LGBTQ Health
- Litigation
- Managed Care
- Medicaid
- Mental Health
- Nondiscrimination
- Oral Health
- Pregnancy
- Prescription Drugs Marketplace
- Prescription Drugs Medicaid
- Privacy and Confidentiality
- Public Health
- Reproductive Health
- Services
- Supreme Court
- Waivers and Demonstrations
- Women's Health
Archives
- February 19, 2019
Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2020
Read moreNational Health Law Program's comments to the U.S. Department of Health and Human Services (HHS) regarding proposed regulations that would continue the administration's campaign to weaken the landmark Affordable Care Act's protections for health care consumers.
- January 16, 2019
National Health Law Program Comments Regarding Proposed Rule Changes on Medicaid Managed Care and CHIP
Read moreThe National Health Law Program in comments to the U.S. Department of Health and Human Services urges it to reject several proposed changes to Medicaid Managed Care and the Children's Health Insurance Program (CHIP) that would weaken oversight of managed care setups, undermine current standards ensuring access to care…
- January 9, 2019
National Health Law Program Comments: Urge CMS to Reject Proposed Changes to Affordable Care Act
Read moreThe National Health Law Program in comments to HHS urge it to reject the Trump administration's proposed rule change to the Affordable Care Act, called "Patient Protection and Affordable Care Act; Exchange Program Integrity NPRM." The comments outline why Trump's proposed changes to the ACA is yet another attempt…
- December 21, 2018
Comments Urging HIV Prevention Drug be Designated an ACA “A” Recommended Service
Read morePeople who are at risk for HIV can prevent infection by taking a daily medication - Pre Exposure Prophylaxis (PrEP). However, many cannot access PrEP due to its high cost. The Affordable Care Act (ACA) recognizes that even small investments in preventive screenings and services can yield significant cost…
- December 18, 2018
Are Rights A Reality? Evaluating Federal Civil Rights Enforcement
Read moreThe National Health Law Program has urged the U.S. Commission on Civil Rights to investigate the "ways in which the Trump administration has actively worked to dismantle important federal civil rights laws that exist to protect the health rights of low-income people, people of color, LGBTQ people, immigrants, and…
- December 14, 2018
Comments to the FDA Urging Approval of Over the Counter Naloxone
Read moreThe National Health Law Program strongly urges the Food and Drug Administration (FDA) to initiate the process of moving at least one naloxone product from prescription to over the counter (OTC) status. Naloxone, a safe and effective medication, reverses opioid overdose if given in time, but is often not…